Contact
Please use this form to send email to PR contact of this press release:
TRACON Pharmaceuticals Presents Final Updated Phase 1b Results for TRC105 in Combination with Inlyta® in Renal Cell Carcinoma at the ESMO 2016 Congress
TO: